

Mobocertinib Study 101

PRELIMINARY SCORE

CURATIVE



NON-CURATIVE



ADJUSTMENTS

Quality of life



Serious and disabling adverse effects



More serious and disabling adverse events observed



Other adjustments



Mobocertinib Study 101

FINAL SCORE

CURATIVE



Overall Survival / Disease-Free Survival / Pathological Complete Response

NON-CURATIVE



Overall Survival



Progression-Free Survival



Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate



Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

INFORMATION

Tumour type: Thoracic Malignancies

Therapeutic Indication: Locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations, with progression on or after platinum-based ChT

Experimental Arm: Mobocertinib

Control Arm: Single arm



